MAP3K8 (Thr290) Polyclonal Antibody

$Formalin-fixed and paraffin embedded human colon carcinoma labeled with Anti Phospho-MAP3K8\/Tpl2 (Thr290) Polyclonal Antibody, Unconjugated (bs-3455R) at 1:200 followed by conjugation to the secondary antibody and DAB staining$

Formalin-fixed and paraffin embedded human colon carcinoma labeled with Anti Phospho-MAP3K8\/Tpl2 (Thr290) Polyclonal Antibody, Unconjugated (bs-3455R) at 1:200 followed by conjugation to the secondary antibody and DAB staining

Applications

ELISA
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)

Reactivity

Human
Rat

Predicted Reactivity

Mouse
Dog
Cow
Pig
Horse
Chicken
Rabbit

Overview
Catalog #	bs-3455R
Product Name	MAP3K8 (Thr290) Polyclonal Antibody
Applications	ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC)
Specificity	This phosphorylation site is homologous across the listed species.
Reactivity	Human, Rat
Predicted Reactivity	Mouse, Dog, Cow, Pig, Horse, Chicken, Rabbit
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic phosphopeptide derived from human MAP3K8/Tpl2 around the phosphorylation site of Thr290
Modification Site	Thr290
Clonality	Polyclonal
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	1326
Swiss Prot	P41279
Subcellular location	Cytoplasm
Synonyms	COT; EST; ESTF; TPL2; MEKK8; Tpl-2; c-COT; Mitogen-activated protein kinase kinase kinase 8; Cancer Osaka thyroid oncogene; Proto-oncogene c-Cot; Serine/threonine-protein kinase cot; Tumor progression locus 2; MAP3K8
Background	Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant.
Application Dilution
ELISA	1:500-1000
IHC-P	1:200-400
IHC-F	1:100-500
IF(IHC-P)	1:50-200
IF(IHC-F)	1:50-200
IF(ICC)	1:50-200